Bristol Myers Squibb’s deucravacitinib meets co-primary endpoints in psoriasis study

This article was originally published here

Deucravacitinib, a novel, oral and selective tyrosine kinase 2 (TYK2) inhibitor, is being assessed in clinical studies across multiple immune-mediated diseases such as psoriasis, psoriatic arthritis, lupus and

The post Bristol Myers Squibb’s deucravacitinib meets co-primary endpoints in psoriasis study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply